1132 related articles for article (PubMed ID: 30642552)
1. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
2. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
4. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
[TBL] [Abstract][Full Text] [Related]
5. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
7. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.
Liam CK; Yew CY; Pang YK; Wong CK; Poh ME; Tan JL; Soo CI; Loh TC; Chin KK; Munusamy V; Liam YS; Ibrahim NH
BMC Cancer; 2023 Jul; 23(1):659. PubMed ID: 37452277
[TBL] [Abstract][Full Text] [Related]
8. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
9. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
[TBL] [Abstract][Full Text] [Related]
11. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
Takamori S; Toyokawa G; Takada K; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Jan; 19(1):12-16. PubMed ID: 28739315
[TBL] [Abstract][Full Text] [Related]
13. [A Real-world Study on the Expression Characteristics of PD-L1 in Patients
with Advanced EGFR Positive NSCLC and Its Relationship with the
Therapeutic Efficacy of EGFR-TKIs].
Chen R; Gao X; Xu F; Zhang S; Ma L; Hu B
Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):217-227. PubMed ID: 37035884
[TBL] [Abstract][Full Text] [Related]
14. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
16. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
[TBL] [Abstract][Full Text] [Related]
17. Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
Ruiz G; Enrico D; Mahmoud YD; Ruiz A; Cantarella MF; Leguina L; Barberis M; Beña A; Brest E; Starapoli S; Mendoza Bertelli A; Tsou F; Pupareli C; Coppola MP; Scocimarro A; Sena S; Levit P; Perfetti A; Aman E; Girotti MR; Arrieta O; Martín C; Salanova R
Thorac Cancer; 2024 Apr; 15(11):895-905. PubMed ID: 38456253
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.
Bylicki O; Paleiron N; Margery J; Guisier F; Vergnenegre A; Robinet G; Auliac JB; Gervais R; Chouaid C
Target Oncol; 2017 Oct; 12(5):563-569. PubMed ID: 28624922
[TBL] [Abstract][Full Text] [Related]
19. Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.
Ozaki Y; Muto S; Takagi H; Watanabe M; Inoue T; Fukuhara M; Yamaura T; Okabe N; Matsumura Y; Hasegawa T; Ohsugi J; Hoshino M; Shio Y; Tanaka D; Nanamiya H; Imai JI; Isogai T; Watanabe S; Suzuki H
Cancer Immunol Immunother; 2020 Jan; 69(1):127-134. PubMed ID: 31807880
[TBL] [Abstract][Full Text] [Related]
20. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
